Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB

Core Viewpoint - Karolinska Development AB has successfully completed a rights issue of Series B shares, achieving approximately 57% subscription, and will change its name to KDventures AB, effective around 10 February 2026 [2][3][10]. Rights Issue Outcome - The rights issue was subscribed to approximately 57%, with 21% through subscription rights and 2% without [3][5]. - The company will receive approximately SEK 115.2 million before issue costs, with a portion subject to ISP approval [3][6]. - If ISP approval is not obtained, the proceeds will be approximately SEK 114.9 million [6]. Share Allotment and Capital Increase - The allotment of shares was resolved on 28 January 2026, with a portion subject to ISP approval if it exceeds 9.99% of total voting rights [4]. - Assuming ISP approval, share capital will increase by approximately SEK 3,841,666.64, raising the total from SEK 2,700,775.94 to SEK 6,542,442.58, resulting in a dilution effect of approximately 59% [8]. - If ISP approval is not granted, the increase will be approximately SEK 3,830,431.43, with a dilution effect of approximately 58.9% [9]. Company Name Change - The company will officially change its name to KDventures AB, with a new trading symbol and short name on Nasdaq Stockholm [10][18]. - The new website will be launched at www.kd-ventures.com [10]. Trading and Conversion - Trading in paid subscribed shares (BTA) will occur under the short name KDEV B until 12 February 2026, with conversion into shares expected around 16 February 2026 [12]. Company Overview - Karolinska Development AB is a Nordic life sciences investment company focused on breakthrough medical innovations and advancing them into commercial products [15][16]. - The company has a portfolio of eleven companies targeting innovative treatments for serious diseases [17].